Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells

Código QR

Luteolin inhibits lung metastasis, cell migration, and viability of triple-negative breast cancer cells

Matthew T Cook,1,2 Yayun Liang,1,2 Cynthia Besch-Williford,3 Salman M Hyder1,2 1Department of Biomedical Sciences, 2Dalton Cardiovascular Research Center, University of Missouri, 3IDEXX BioResearch, Columbia, MO, USA Abstract: Most breast cancer-related deaths from triple-negative breast cancer (TNB...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cook MT, Liang Y, Besch-Williford C, Hyder SM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	luteolin triple-negative breast cancer metastasis cell migration apoptosis VEGF Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/fd3d22c61bf7404f941c2b88be5ac680
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Mechanism of metastasis suppression by luteolin in breast cancer
por: Cook MT
Publicado: (2018)

APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice
por: Liang Y, et al.
Publicado: (2019)

Delivery luteolin with folacin-modified nanoparticle for glioma therapy
por: Wu C, et al.
Publicado: (2019)

Luteolin Inhibits Breast Cancer Stemness and Enhances Chemosensitivity through the Nrf2-Mediated Pathway
por: Kuen-Jang Tsai, et al.
Publicado: (2021)

Palmatine sensitizes chemoresistant triple negative breast cancer cells via efflux inhibition of multidrug resistant protein 1.
por: Selase Ativui, et al.
Publicado: (2021)

Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer
por: Hongyuan Zhao, et al.
Publicado: (2021)

Encapsulating Halofuginone Hydrobromide in TPGS Polymeric Micelles Enhances Efficacy Against Triple-Negative Breast Cancer Cells
por: Zuo R, et al.
Publicado: (2021)

lncRNA prostate cancer-associated transcript 18 upregulates activating transcription factor 7 to prevent metastasis of triple-negative breast cancer via sponging miR-103a-3p
por: Jinfeng Zhang, et al.
Publicado: (2021)

Establishment and validation of an individualized macrophage-related gene signature to predict overall survival in patients with triple negative breast cancer
por: Peng Su, et al.
Publicado: (2021)

Potential clinically useful prognostic biomarkers in triple-negative breast cancer: preliminary results of a retrospective analysis
por: Ilie SM, et al.
Publicado: (2018)

Current advances in biomarkers for targeted therapy in triple-negative breast cancer
por: Fleisher B, et al.
Publicado: (2016)

Angiogenesis and Tumor Progression Inhibition of Cyclooxygenase-2 Selective Inhibitor Celecoxib Associated with Poly (lactic-co-glycolic acid) in Tumor Cell Line Resistant to Chemotherapy
por: Roa,Ignacio, et al.
Publicado: (2017)

Antiangiogenic therapy for breast cancer with triple negative phenotype
por: Inna P. Ganshina, et al.
Publicado: (2021)

Molecular-Genetic Portrait of Breast Cancer with Triple Negative Phenotype
por: Marina K. Ibragimova, et al.
Publicado: (2021)

A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts
por: Liang Y, et al.
Publicado: (2018)

Real-World Data from a Refractory Triple-Negative Breast Cancer Cohort Selected Using a Clinical Data Warehouse Approach
por: Hana Kim, et al.
Publicado: (2021)

Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel–cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines
por: Ye J, et al.
Publicado: (2016)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang X, et al.
Publicado: (2021)

Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers
por: Al-saraireh YM, et al.
Publicado: (2021)

Prognostic and clinicopathological values of tissue expression of MFAP5 and ITM2A in triple-negative breast cancer: an immunohistochemical study
por: Abdulwahab Abuderman, et al.
Publicado: (2020)

The Clinical Value of Chemotherapy Combined With Capecitabine in Triple-Negative Breast Cancer—A Meta-Analysis
por: Zilin Zhang, et al.
Publicado: (2021)

Tumor suppressive function of Matrin 3 in the basal-like breast cancer
por: Yang,Jaehyuk, et al.
Publicado: (2020)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Sara Bravaccini, et al.
Publicado: (2021)

Influence of Stabilizer on the Development of Luteolin Nanosuspension for Cutaneous Delivery: An In Vitro and In Vivo Evaluation
por: Mohammed Elmowafy, et al.
Publicado: (2021)

miR-29b-3p promotes progression of MDA-mB-231 triple-negative breast cancer cells through downregulating TRAF3
por: Zhang,Bao, et al.
Publicado: (2019)

Kinome-Wide siRNA Screening Identifies DYRK1B as a Potential Therapeutic Target for Triple-Negative Breast Cancer Cells
por: Chia-Che Chang, et al.
Publicado: (2021)

A Case of Triple-Negative Breast Cancer with Germline Pathogenic Variants in Both BRCA1 and BRCA2
por: Miyuki Kitahara, et al.
Publicado: (2021)

Immunotherapy for triple-negative breast cancer: A molecular insight into the microenvironment, treatment, and resistance
por: Xupeng Bai, et al.
Publicado: (2021)

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment
por: da Silva JL, et al.
Publicado: (2021)

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
por: Ieni A, et al.
Publicado: (2016)

Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study
por: Luis de la Cruz-Merino, et al.
Publicado: (2021)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

A Combined Nomogram Model to Predict Disease-free Survival in Triple-Negative Breast Cancer Patients With Neoadjuvant Chemotherapy
por: Bingqing Xia, et al.
Publicado: (2021)

Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
por: Mirjana Prvanović, et al.
Publicado: (2021)

Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases
por: Seung-Uon Shin, et al.
Publicado: (2021)

Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer
por: Li X, et al.
Publicado: (2020)

Novel therapeutic strategies for patients with metastatic triple-negative breast cancer
por: Inna P. Ganshina, et al.
Publicado: (2021)

Reversing an Oncogenic Epithelial-to-Mesenchymal Transition Program in Breast Cancer Reveals Actionable Immune Suppressive Pathways
por: Michelle M. Williams, et al.
Publicado: (2021)

Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells
por: Veronica Vella, et al.
Publicado: (2021)

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification
por: Yubao Zhang, et al.
Publicado: (2021)